These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33848310)

  • 1. Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.
    Rashid MA; Muneer S; Wang T; Alhamhoom Y; Rintoul L; Izake EL; Islam N
    PLoS One; 2021; 16(4):e0249683. PubMed ID: 33848310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of meropenem dry powder inhaler formulation for pulmonary drug delivery.
    Muneer S; Wang T; Rintoul L; Ayoko GA; Islam N; Izake EL
    Int J Pharm; 2020 Sep; 587():119684. PubMed ID: 32736016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
    Yu J; Chan HK; Gengenbach T; Denman JA
    Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.
    Rashid MA; Muneer S; Mendhi J; Sabuj MZR; Alhamhoom Y; Xiao Y; Wang T; Izake EL; Islam N
    Int J Pharm; 2021 Oct; 608():121122. PubMed ID: 34560207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery.
    Rashid MA; Elgied AA; Alhamhoom Y; Chan E; Rintoul L; Allahham A; Islam N
    Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31052466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
    Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
    Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X; Li J; Wen X; Ma S; An Y; Zhang X; Guan J; Mao S
    Int J Pharm; 2024 Oct; 664():124609. PubMed ID: 39163928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
    Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
    Son YJ; Worth Longest P; Hindle M
    Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
    Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
    AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
    Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
    Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
    Momin MAM; Tucker IG; Das SC
    Drug Dev Ind Pharm; 2019 Jul; 45(7):1205-1213. PubMed ID: 30990097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
    Liu T; Tong S; Liao Q; Pan L; Cheng M; Rantanen J; Cun D; Yang M
    Int J Pharm; 2023 Mar; 635():122702. PubMed ID: 36773729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalable lactose-based dry powder formulations of low molecular weight heparin.
    Bai S; Gupta V; Ahsan F
    J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23(2):97-104. PubMed ID: 19778265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation.
    Schoubben A; Vivani R; Paolantoni M; Perinelli DR; Gioiello A; Macchiarulo A; Ricci M
    Eur J Pharm Sci; 2019 Mar; 130():54-64. PubMed ID: 30677523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.